Alterity aligns with regulatory pathway for neurology drug

• Alterity Therapeutics (NASDAQ:ATHE) received official FDA meeting minutes confirming the regulatory layout for its Phase 3 Multiple System Atrophy drug trial.
• The regulatory guidance confirms that a single pivotal efficacy study supported by existing Phase 2 findings can power a potential marketing application.
• The company plans to finalize its clinical study protocol to remain on track to initiate Phase 3 trial activities before year-end 2026.

Alterity Therapeutics (NASDAQ:ATHE) announced it received official End-of-Phase-2 meeting minutes from the FDA confirming the registrational design pathways for its neurodegenerative drug candidate ATH434.

The feedback validates a streamlined clinical development strategy to address Multiple System Atrophy, a rare and debilitating neurological disorder with no currently approved disease-modifying treatments.

"The official meeting minutes confirm the alignment we reached with the FDA and provide a well-defined clinical development strategy for registration," said Alterity Therapeutics Chief Executive Officer David Stamler.

The upcoming pivotal trial will randomize roughly 200 patients under a one-to-one ratio to receive a twice-daily 50 mg dose or a matching placebo for 12 months.

The primary clinical tracking metric relies upon the 11-item Unified Multiple System Atrophy Rating Scale functional framework to evaluate changes in everyday patient living activities.

The Melbourne, Australia-based biotechnology corporation expects to leverage data from its completed Phase 2 study as the required federal confirmatory evidence to back the final marketing filing.